Procaps Group S.A.
Procaps Group S.A. (PROC) Stock Competitors & Peer Comparison
See (PROC) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PROC | $1.01 | +0.00% | 102.1M | 1.53 | $0.66 | N/A |
| TAK | $18.76 | +0.51% | 58.9B | 81.11 | $0.23 | +3.20% |
| ZTS | $126.49 | -0.62% | 56.7B | 21.39 | $6.02 | +1.58% |
| HLN | $11.13 | +0.23% | 50.8B | 25.04 | $0.45 | +1.56% |
| TEVA | $33.88 | -1.31% | 39.2B | 28.27 | $1.21 | N/A |
| VTRS | $15.91 | -0.47% | 18.3B | -5.09 | -$3.13 | +3.02% |
| RGC | $27.43 | -18.02% | 14.4B | -2917.00 | -$0.01 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $127.88 | -1.71% | 12.9B | 27.54 | $4.67 | N/A |
| ELAN | $24.66 | -2.14% | 12.4B | 356.71 | $0.07 | N/A |
Stock Comparison
PROC vs TAK Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TAK has a market cap of 58.9B. Regarding current trading prices, PROC is priced at $1.01, while TAK trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TAK's P/E ratio is 81.11. In terms of profitability, PROC's ROE is -2.22%, compared to TAK's ROE of +0.02%. Regarding short-term risk, PROC is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TAK's competition here
PROC vs ZTS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ZTS has a market cap of 56.7B. Regarding current trading prices, PROC is priced at $1.01, while ZTS trades at $126.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ZTS's P/E ratio is 21.39. In terms of profitability, PROC's ROE is -2.22%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, PROC is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ZTS's competition here
PROC vs HLN Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, HLN has a market cap of 50.8B. Regarding current trading prices, PROC is priced at $1.01, while HLN trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas HLN's P/E ratio is 25.04. In terms of profitability, PROC's ROE is -2.22%, compared to HLN's ROE of +0.15%. Regarding short-term risk, PROC is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check HLN's competition here
PROC vs TEVA Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TEVA has a market cap of 39.2B. Regarding current trading prices, PROC is priced at $1.01, while TEVA trades at $33.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TEVA's P/E ratio is 28.27. In terms of profitability, PROC's ROE is -2.22%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, PROC is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TEVA's competition here
PROC vs VTRS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, VTRS has a market cap of 18.3B. Regarding current trading prices, PROC is priced at $1.01, while VTRS trades at $15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas VTRS's P/E ratio is -5.09. In terms of profitability, PROC's ROE is -2.22%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, PROC is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check VTRS's competition here
PROC vs RGC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, RGC has a market cap of 14.4B. Regarding current trading prices, PROC is priced at $1.01, while RGC trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas RGC's P/E ratio is -2917.00. In terms of profitability, PROC's ROE is -2.22%, compared to RGC's ROE of -0.62%. Regarding short-term risk, PROC is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check RGC's competition here
PROC vs ITCI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, PROC is priced at $1.01, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ITCI's P/E ratio is -180.64. In terms of profitability, PROC's ROE is -2.22%, compared to ITCI's ROE of -0.04%. Regarding short-term risk, PROC and ITCI have similar daily volatility (0.00).Check ITCI's competition here
PROC vs NBIX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, NBIX has a market cap of 12.9B. Regarding current trading prices, PROC is priced at $1.01, while NBIX trades at $127.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas NBIX's P/E ratio is 27.54. In terms of profitability, PROC's ROE is -2.22%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, PROC is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check NBIX's competition here
PROC vs ELAN Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ELAN has a market cap of 12.4B. Regarding current trading prices, PROC is priced at $1.01, while ELAN trades at $24.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ELAN's P/E ratio is 356.71. In terms of profitability, PROC's ROE is -2.22%, compared to ELAN's ROE of +0.01%. Regarding short-term risk, PROC is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ELAN's competition here
PROC vs RDY Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, RDY has a market cap of 12.1B. Regarding current trading prices, PROC is priced at $1.01, while RDY trades at $14.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas RDY's P/E ratio is 19.31. In terms of profitability, PROC's ROE is -2.22%, compared to RDY's ROE of +0.16%. Regarding short-term risk, PROC is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check RDY's competition here
PROC vs CTLT Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, PROC is priced at $1.01, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CTLT's P/E ratio is -27.84. In terms of profitability, PROC's ROE is -2.22%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, PROC is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check CTLT's competition here
PROC vs LNTH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, PROC is priced at $1.01, while LNTH trades at $73.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas LNTH's P/E ratio is 30.65. In terms of profitability, PROC's ROE is -2.22%, compared to LNTH's ROE of +0.15%. Regarding short-term risk, PROC is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check LNTH's competition here
PROC vs AMRX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AMRX has a market cap of 4.6B. Regarding current trading prices, PROC is priced at $1.01, while AMRX trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AMRX's P/E ratio is 1450.00. In terms of profitability, PROC's ROE is -2.22%, compared to AMRX's ROE of -0.05%. Regarding short-term risk, PROC is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check AMRX's competition here
PROC vs INDV Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, PROC is priced at $1.01, while INDV trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas INDV's P/E ratio is 34.58. In terms of profitability, PROC's ROE is -2.22%, compared to INDV's ROE of -0.60%. Regarding short-term risk, PROC is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check INDV's competition here
PROC vs SUPN Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, PROC is priced at $1.01, while SUPN trades at $50.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SUPN's P/E ratio is -149.59. In terms of profitability, PROC's ROE is -2.22%, compared to SUPN's ROE of -0.02%. Regarding short-term risk, PROC is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SUPN's competition here
PROC vs HCM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, PROC is priced at $1.01, while HCM trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas HCM's P/E ratio is 5.77. In terms of profitability, PROC's ROE is -2.22%, compared to HCM's ROE of +0.47%. Regarding short-term risk, PROC is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check HCM's competition here
PROC vs BHC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, PROC is priced at $1.01, while BHC trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas BHC's P/E ratio is 6.31. In terms of profitability, PROC's ROE is -2.22%, compared to BHC's ROE of -0.21%. Regarding short-term risk, PROC is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check BHC's competition here
PROC vs DCPH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, PROC is priced at $1.01, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas DCPH's P/E ratio is -11.58. In terms of profitability, PROC's ROE is -2.22%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, PROC is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check DCPH's competition here
PROC vs PAHC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, PAHC has a market cap of 2.1B. Regarding current trading prices, PROC is priced at $1.01, while PAHC trades at $51.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas PAHC's P/E ratio is 23.36. In terms of profitability, PROC's ROE is -2.22%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, PROC is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check PAHC's competition here
PROC vs AVDL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, PROC is priced at $1.01, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, PROC's ROE is -2.22%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, PROC and AVDL have similar daily volatility (0.00).Check AVDL's competition here
PROC vs PRGO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, PRGO has a market cap of 2.1B. Regarding current trading prices, PROC is priced at $1.01, while PRGO trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas PRGO's P/E ratio is -71.26. In terms of profitability, PROC's ROE is -2.22%, compared to PRGO's ROE of -0.01%. Regarding short-term risk, PROC is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check PRGO's competition here
PROC vs HROW Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, HROW has a market cap of 1.9B. Regarding current trading prices, PROC is priced at $1.01, while HROW trades at $52.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas HROW's P/E ratio is -400.00. In terms of profitability, PROC's ROE is -2.22%, compared to HROW's ROE of -0.09%. Regarding short-term risk, PROC is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check HROW's competition here
PROC vs EMBCV Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, PROC is priced at $1.01, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EMBCV's P/E ratio is N/A. In terms of profitability, PROC's ROE is -2.22%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, PROC is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check EMBCV's competition here
PROC vs DVAX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, PROC is priced at $1.01, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas DVAX's P/E ratio is -41.89. In terms of profitability, PROC's ROE is -2.22%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, PROC and DVAX have similar daily volatility (0.00).Check DVAX's competition here
PROC vs ANIP Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, PROC is priced at $1.01, while ANIP trades at $76.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ANIP's P/E ratio is 48.61. In terms of profitability, PROC's ROE is -2.22%, compared to ANIP's ROE of +0.08%. Regarding short-term risk, PROC is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ANIP's competition here
PROC vs TARO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, PROC is priced at $1.01, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TARO's P/E ratio is 30.05. In terms of profitability, PROC's ROE is -2.22%, compared to TARO's ROE of +0.03%. Regarding short-term risk, PROC is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TARO's competition here
PROC vs COLL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, COLL has a market cap of 1.4B. Regarding current trading prices, PROC is priced at $1.01, while COLL trades at $44.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas COLL's P/E ratio is 27.61. In terms of profitability, PROC's ROE is -2.22%, compared to COLL's ROE of +0.24%. Regarding short-term risk, PROC is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check COLL's competition here
PROC vs AMPH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AMPH has a market cap of 1.3B. Regarding current trading prices, PROC is priced at $1.01, while AMPH trades at $27.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AMPH's P/E ratio is 12.62. In terms of profitability, PROC's ROE is -2.22%, compared to AMPH's ROE of +0.15%. Regarding short-term risk, PROC is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check AMPH's competition here
PROC vs ALVO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, PROC is priced at $1.01, while ALVO trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ALVO's P/E ratio is 18.04. In terms of profitability, PROC's ROE is -2.22%, compared to ALVO's ROE of -0.26%. Regarding short-term risk, PROC is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ALVO's competition here
PROC vs EVO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, PROC is priced at $1.01, while EVO trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EVO's P/E ratio is -6.66. In terms of profitability, PROC's ROE is -2.22%, compared to EVO's ROE of -0.17%. Regarding short-term risk, PROC is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check EVO's competition here
PROC vs CRON Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, PROC is priced at $1.01, while CRON trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CRON's P/E ratio is 24.55. In terms of profitability, PROC's ROE is -2.22%, compared to CRON's ROE of +0.03%. Regarding short-term risk, PROC is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check CRON's competition here
PROC vs PCRX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, PCRX has a market cap of 999M. Regarding current trading prices, PROC is priced at $1.01, while PCRX trades at $22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas PCRX's P/E ratio is 49.40. In terms of profitability, PROC's ROE is -2.22%, compared to PCRX's ROE of +0.03%. Regarding short-term risk, PROC is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check PCRX's competition here
PROC vs PETQ Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, PROC is priced at $1.01, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas PETQ's P/E ratio is 83.73. In terms of profitability, PROC's ROE is -2.22%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, PROC is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check PETQ's competition here
PROC vs TLRY Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TLRY has a market cap of 784.7M. Regarding current trading prices, PROC is priced at $1.01, while TLRY trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TLRY's P/E ratio is -0.33. In terms of profitability, PROC's ROE is -2.22%, compared to TLRY's ROE of -1.14%. Regarding short-term risk, PROC is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TLRY's competition here
PROC vs ESPR Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ESPR has a market cap of 687.4M. Regarding current trading prices, PROC is priced at $1.01, while ESPR trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ESPR's P/E ratio is -6.44. In terms of profitability, PROC's ROE is -2.22%, compared to ESPR's ROE of +0.25%. Regarding short-term risk, PROC is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ESPR's competition here
PROC vs IRWD Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, IRWD has a market cap of 644.2M. Regarding current trading prices, PROC is priced at $1.01, while IRWD trades at $3.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas IRWD's P/E ratio is 22.00. In terms of profitability, PROC's ROE is -2.22%, compared to IRWD's ROE of -0.09%. Regarding short-term risk, PROC is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check IRWD's competition here
PROC vs EMBC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EMBC has a market cap of 635.4M. Regarding current trading prices, PROC is priced at $1.01, while EMBC trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EMBC's P/E ratio is 4.55. In terms of profitability, PROC's ROE is -2.22%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, PROC is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check EMBC's competition here
PROC vs CGC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CGC has a market cap of 612.3M. Regarding current trading prices, PROC is priced at $1.01, while CGC trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CGC's P/E ratio is -0.87. In terms of profitability, PROC's ROE is -2.22%, compared to CGC's ROE of -0.53%. Regarding short-term risk, PROC is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check CGC's competition here
PROC vs EBS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EBS has a market cap of 582.6M. Regarding current trading prices, PROC is priced at $1.01, while EBS trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EBS's P/E ratio is 8.27. In terms of profitability, PROC's ROE is -2.22%, compared to EBS's ROE of +0.14%. Regarding short-term risk, PROC is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check EBS's competition here
PROC vs BDSI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, PROC is priced at $1.01, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas BDSI's P/E ratio is 6.82. In terms of profitability, PROC's ROE is -2.22%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, PROC is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check BDSI's competition here
PROC vs KMDA Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, KMDA has a market cap of 507.6M. Regarding current trading prices, PROC is priced at $1.01, while KMDA trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas KMDA's P/E ratio is 25.14. In terms of profitability, PROC's ROE is -2.22%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, PROC is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check KMDA's competition here
PROC vs ORGO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ORGO has a market cap of 506.4M. Regarding current trading prices, PROC is priced at $1.01, while ORGO trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ORGO's P/E ratio is -49.87. In terms of profitability, PROC's ROE is -2.22%, compared to ORGO's ROE of +0.00%. Regarding short-term risk, PROC is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ORGO's competition here
PROC vs SIGA Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SIGA has a market cap of 483.4M. Regarding current trading prices, PROC is priced at $1.01, while SIGA trades at $6.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SIGA's P/E ratio is 6.55. In terms of profitability, PROC's ROE is -2.22%, compared to SIGA's ROE of +0.35%. Regarding short-term risk, PROC is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SIGA's competition here
PROC vs SNDL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SNDL has a market cap of 406.9M. Regarding current trading prices, PROC is priced at $1.01, while SNDL trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SNDL's P/E ratio is -6.08. In terms of profitability, PROC's ROE is -2.22%, compared to SNDL's ROE of -0.08%. Regarding short-term risk, PROC is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SNDL's competition here
PROC vs AQST Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AQST has a market cap of 392.3M. Regarding current trading prices, PROC is priced at $1.01, while AQST trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AQST's P/E ratio is -5.64. In terms of profitability, PROC's ROE is -2.22%, compared to AQST's ROE of +1.40%. Regarding short-term risk, PROC is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check AQST's competition here
PROC vs ALIM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, PROC is priced at $1.01, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ALIM's P/E ratio is 5.28. In terms of profitability, PROC's ROE is -2.22%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, PROC is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ALIM's competition here
PROC vs EOLS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EOLS has a market cap of 283.3M. Regarding current trading prices, PROC is priced at $1.01, while EOLS trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EOLS's P/E ratio is -4.86. In terms of profitability, PROC's ROE is -2.22%, compared to EOLS's ROE of +4.83%. Regarding short-term risk, PROC is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check EOLS's competition here
PROC vs LFCR Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, LFCR has a market cap of 267.1M. Regarding current trading prices, PROC is priced at $1.01, while LFCR trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas LFCR's P/E ratio is -5.61. In terms of profitability, PROC's ROE is -2.22%, compared to LFCR's ROE of -2.33%. Regarding short-term risk, PROC is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check LFCR's competition here
PROC vs LNDC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, PROC is priced at $1.01, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas LNDC's P/E ratio is -4.04. In terms of profitability, PROC's ROE is -2.22%, compared to LNDC's ROE of -15.33%. Regarding short-term risk, PROC is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check LNDC's competition here
PROC vs TYHT Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, PROC is priced at $1.01, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TYHT's P/E ratio is -1.61. In terms of profitability, PROC's ROE is -2.22%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, PROC is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TYHT's competition here
PROC vs ACB Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ACB has a market cap of 213.8M. Regarding current trading prices, PROC is priced at $1.01, while ACB trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ACB's P/E ratio is -3.46. In terms of profitability, PROC's ROE is -2.22%, compared to ACB's ROE of +0.07%. Regarding short-term risk, PROC is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ACB's competition here
PROC vs BGM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, BGM has a market cap of 208.6M. Regarding current trading prices, PROC is priced at $1.01, while BGM trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas BGM's P/E ratio is -3.59. In terms of profitability, PROC's ROE is -2.22%, compared to BGM's ROE of -0.01%. Regarding short-term risk, PROC is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check BGM's competition here
PROC vs DERM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, DERM has a market cap of 195.9M. Regarding current trading prices, PROC is priced at $1.01, while DERM trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas DERM's P/E ratio is -24.29. In terms of profitability, PROC's ROE is -2.22%, compared to DERM's ROE of -0.40%. Regarding short-term risk, PROC is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check DERM's competition here
PROC vs OGI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, OGI has a market cap of 194.6M. Regarding current trading prices, PROC is priced at $1.01, while OGI trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas OGI's P/E ratio is 13.09. In terms of profitability, PROC's ROE is -2.22%, compared to OGI's ROE of +0.05%. Regarding short-term risk, PROC is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check OGI's competition here
PROC vs REPH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, PROC is priced at $1.01, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas REPH's P/E ratio is -8.04. In terms of profitability, PROC's ROE is -2.22%, compared to REPH's ROE of -0.22%. Regarding short-term risk, PROC is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check REPH's competition here
PROC vs THTX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, PROC is priced at $1.01, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas THTX's P/E ratio is -17.84. In terms of profitability, PROC's ROE is -2.22%, compared to THTX's ROE of +0.38%. Regarding short-term risk, PROC is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check THTX's competition here
PROC vs SCTL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, PROC is priced at $1.01, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SCTL's P/E ratio is -7.86. In terms of profitability, PROC's ROE is -2.22%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, PROC is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SCTL's competition here
PROC vs TKNO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TKNO has a market cap of 110.3M. Regarding current trading prices, PROC is priced at $1.01, while TKNO trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TKNO's P/E ratio is -6.24. In terms of profitability, PROC's ROE is -2.22%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, PROC is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TKNO's competition here
PROC vs CRDL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CRDL has a market cap of 100M. Regarding current trading prices, PROC is priced at $1.01, while CRDL trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CRDL's P/E ratio is -3.33. In terms of profitability, PROC's ROE is -2.22%, compared to CRDL's ROE of -2.03%. Regarding short-term risk, PROC is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check CRDL's competition here
PROC vs OPTN Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, PROC is priced at $1.01, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas OPTN's P/E ratio is -4.42. In terms of profitability, PROC's ROE is -2.22%, compared to OPTN's ROE of +0.47%. Regarding short-term risk, PROC and OPTN have similar daily volatility (0.00).Check OPTN's competition here
PROC vs IXHL Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, IXHL has a market cap of 96.4M. Regarding current trading prices, PROC is priced at $1.01, while IXHL trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas IXHL's P/E ratio is -0.38. In terms of profitability, PROC's ROE is -2.22%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, PROC is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check IXHL's competition here
PROC vs ZOM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, PROC is priced at $1.01, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ZOM's P/E ratio is -1.62. In terms of profitability, PROC's ROE is -2.22%, compared to ZOM's ROE of -0.59%. Regarding short-term risk, PROC is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ZOM's competition here
PROC vs GRVI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, PROC is priced at $1.01, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas GRVI's P/E ratio is 26.05. In terms of profitability, PROC's ROE is -2.22%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, PROC is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check GRVI's competition here
PROC vs ASRT Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ASRT has a market cap of 76M. Regarding current trading prices, PROC is priced at $1.01, while ASRT trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ASRT's P/E ratio is -2.63. In terms of profitability, PROC's ROE is -2.22%, compared to ASRT's ROE of -0.27%. Regarding short-term risk, PROC is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ASRT's competition here
PROC vs ZYNE Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, PROC is priced at $1.01, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, PROC's ROE is -2.22%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, PROC is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ZYNE's competition here
PROC vs SSIC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, PROC is priced at $1.01, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SSIC's P/E ratio is 11.93. In terms of profitability, PROC's ROE is -2.22%, compared to SSIC's ROE of -0.00%. Regarding short-term risk, PROC is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SSIC's competition here
PROC vs VLNS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, PROC is priced at $1.01, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas VLNS's P/E ratio is -1.03. In terms of profitability, PROC's ROE is -2.22%, compared to VLNS's ROE of N/A. Regarding short-term risk, PROC is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check VLNS's competition here
PROC vs DRRX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, PROC is priced at $1.01, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas DRRX's P/E ratio is -4.44. In terms of profitability, PROC's ROE is -2.22%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, PROC and DRRX have similar daily volatility (0.00).Check DRRX's competition here
PROC vs CPIX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CPIX has a market cap of 58.3M. Regarding current trading prices, PROC is priced at $1.01, while CPIX trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CPIX's P/E ratio is -16.25. In terms of profitability, PROC's ROE is -2.22%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, PROC is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check CPIX's competition here
PROC vs JUPW Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, PROC is priced at $1.01, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas JUPW's P/E ratio is -2.41. In terms of profitability, PROC's ROE is -2.22%, compared to JUPW's ROE of -0.99%. Regarding short-term risk, PROC is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check JUPW's competition here
PROC vs ALVOW Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ALVOW has a market cap of 48.7M. Regarding current trading prices, PROC is priced at $1.01, while ALVOW trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ALVOW's P/E ratio is N/A. In terms of profitability, PROC's ROE is -2.22%, compared to ALVOW's ROE of -0.26%. Regarding short-term risk, PROC and ALVOW have similar daily volatility (0.00).Check ALVOW's competition here
PROC vs INCR Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, INCR has a market cap of 48.1M. Regarding current trading prices, PROC is priced at $1.01, while INCR trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas INCR's P/E ratio is -1.76. In terms of profitability, PROC's ROE is -2.22%, compared to INCR's ROE of -0.17%. Regarding short-term risk, PROC is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check INCR's competition here
PROC vs ZYBT Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ZYBT has a market cap of 41.7M. Regarding current trading prices, PROC is priced at $1.01, while ZYBT trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ZYBT's P/E ratio is -14.67. In terms of profitability, PROC's ROE is -2.22%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, PROC is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ZYBT's competition here
PROC vs QLI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, PROC is priced at $1.01, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas QLI's P/E ratio is -4.92. In terms of profitability, PROC's ROE is -2.22%, compared to QLI's ROE of -0.16%. Regarding short-term risk, PROC and QLI have similar daily volatility (0.00).Check QLI's competition here
PROC vs RMTI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, RMTI has a market cap of 37.5M. Regarding current trading prices, PROC is priced at $1.01, while RMTI trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas RMTI's P/E ratio is -5.29. In terms of profitability, PROC's ROE is -2.22%, compared to RMTI's ROE of -0.17%. Regarding short-term risk, PROC is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check RMTI's competition here
PROC vs SCYX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SCYX has a market cap of 32.9M. Regarding current trading prices, PROC is priced at $1.01, while SCYX trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SCYX's P/E ratio is -1.54. In terms of profitability, PROC's ROE is -2.22%, compared to SCYX's ROE of -0.54%. Regarding short-term risk, PROC is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SCYX's competition here
PROC vs HEXO Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, PROC is priced at $1.01, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas HEXO's P/E ratio is -0.26. In terms of profitability, PROC's ROE is -2.22%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, PROC is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check HEXO's competition here
PROC vs TXMD Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TXMD has a market cap of 26.6M. Regarding current trading prices, PROC is priced at $1.01, while TXMD trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TXMD's P/E ratio is 230.00. In terms of profitability, PROC's ROE is -2.22%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, PROC is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TXMD's competition here
PROC vs CYTH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, PROC is priced at $1.01, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas CYTH's P/E ratio is -0.80. In terms of profitability, PROC's ROE is -2.22%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, PROC and CYTH have similar daily volatility (0.00).Check CYTH's competition here
PROC vs EVOK Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, PROC is priced at $1.01, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas EVOK's P/E ratio is -7.97. In terms of profitability, PROC's ROE is -2.22%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, PROC and EVOK have similar daily volatility (0.00).Check EVOK's competition here
PROC vs AYTU Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AYTU has a market cap of 18.6M. Regarding current trading prices, PROC is priced at $1.01, while AYTU trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AYTU's P/E ratio is -0.67. In terms of profitability, PROC's ROE is -2.22%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, PROC is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check AYTU's competition here
PROC vs APUS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, APUS has a market cap of 17.5M. Regarding current trading prices, PROC is priced at $1.01, while APUS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas APUS's P/E ratio is -3.39. In terms of profitability, PROC's ROE is -2.22%, compared to APUS's ROE of -1.40%. Regarding short-term risk, PROC is less volatile compared to APUS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check APUS's competition here
PROC vs TLPH Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, TLPH has a market cap of 15.8M. Regarding current trading prices, PROC is priced at $1.01, while TLPH trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas TLPH's P/E ratio is -2.02. In terms of profitability, PROC's ROE is -2.22%, compared to TLPH's ROE of -1.26%. Regarding short-term risk, PROC is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check TLPH's competition here
PROC vs ACRX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, PROC is priced at $1.01, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ACRX's P/E ratio is -0.31. In terms of profitability, PROC's ROE is -2.22%, compared to ACRX's ROE of -1.26%. Regarding short-term risk, PROC is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ACRX's competition here
PROC vs QNTM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, QNTM has a market cap of 14.2M. Regarding current trading prices, PROC is priced at $1.01, while QNTM trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas QNTM's P/E ratio is -0.39. In terms of profitability, PROC's ROE is -2.22%, compared to QNTM's ROE of -3.85%. Regarding short-term risk, PROC is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check QNTM's competition here
PROC vs AGRX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, PROC is priced at $1.01, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas AGRX's P/E ratio is -0.89. In terms of profitability, PROC's ROE is -2.22%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, PROC is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check AGRX's competition here
PROC vs COSM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, COSM has a market cap of 10.2M. Regarding current trading prices, PROC is priced at $1.01, while COSM trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas COSM's P/E ratio is -0.48. In terms of profitability, PROC's ROE is -2.22%, compared to COSM's ROE of -0.74%. Regarding short-term risk, PROC is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check COSM's competition here
PROC vs BFRI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, BFRI has a market cap of 10M. Regarding current trading prices, PROC is priced at $1.01, while BFRI trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas BFRI's P/E ratio is -0.57. In terms of profitability, PROC's ROE is -2.22%, compared to BFRI's ROE of +29.95%. Regarding short-term risk, PROC is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check BFRI's competition here
PROC vs YCBD Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, YCBD has a market cap of 9.9M. Regarding current trading prices, PROC is priced at $1.01, while YCBD trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas YCBD's P/E ratio is -0.86. In terms of profitability, PROC's ROE is -2.22%, compared to YCBD's ROE of -0.15%. Regarding short-term risk, PROC is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check YCBD's competition here
PROC vs NLTX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, PROC is priced at $1.01, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas NLTX's P/E ratio is -0.28. In terms of profitability, PROC's ROE is -2.22%, compared to NLTX's ROE of -0.40%. Regarding short-term risk, PROC is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check NLTX's competition here
PROC vs LCI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, PROC is priced at $1.01, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas LCI's P/E ratio is -0.04. In terms of profitability, PROC's ROE is -2.22%, compared to LCI's ROE of +1.66%. Regarding short-term risk, PROC is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check LCI's competition here
PROC vs BGXX Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, PROC is priced at $1.01, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas BGXX's P/E ratio is -0.76. In terms of profitability, PROC's ROE is -2.22%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, PROC and BGXX have similar daily volatility (0.00).Check BGXX's competition here
PROC vs ADMP Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, PROC is priced at $1.01, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas ADMP's P/E ratio is -0.08. In terms of profitability, PROC's ROE is -2.22%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, PROC is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check ADMP's competition here
PROC vs GELS Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, GELS has a market cap of 7M. Regarding current trading prices, PROC is priced at $1.01, while GELS trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas GELS's P/E ratio is -1.49. In terms of profitability, PROC's ROE is -2.22%, compared to GELS's ROE of -0.43%. Regarding short-term risk, PROC is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check GELS's competition here
PROC vs SBFM Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SBFM has a market cap of 5.7M. Regarding current trading prices, PROC is priced at $1.01, while SBFM trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SBFM's P/E ratio is 0.22. In terms of profitability, PROC's ROE is -2.22%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, PROC is less volatile compared to SBFM. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SBFM's competition here
PROC vs SNOA Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, SNOA has a market cap of 5M. Regarding current trading prices, PROC is priced at $1.01, while SNOA trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas SNOA's P/E ratio is -1.47. In terms of profitability, PROC's ROE is -2.22%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, PROC is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check SNOA's competition here
PROC vs MNK Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, PROC is priced at $1.01, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas MNK's P/E ratio is -0.44. In terms of profitability, PROC's ROE is -2.22%, compared to MNK's ROE of +0.11%. Regarding short-term risk, PROC is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check MNK's competition here
PROC vs FLGC Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, PROC is priced at $1.01, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas FLGC's P/E ratio is -0.19. In terms of profitability, PROC's ROE is -2.22%, compared to FLGC's ROE of -0.82%. Regarding short-term risk, PROC is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for PROC.Check FLGC's competition here
PROC vs GHSI Comparison February 2026
PROC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PROC stands at 102.1M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, PROC is priced at $1.01, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PROC currently has a P/E ratio of 1.53, whereas GHSI's P/E ratio is -0.79. In terms of profitability, PROC's ROE is -2.22%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, PROC and GHSI have similar daily volatility (0.00).Check GHSI's competition here